Drug intelligence / Profile preview

WH003

Development stage: Preclinical
Lead developer: Beijing Wehand-Bio Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

WH003 is an investigational oral nano-formulation of a natural medicine-derived small molecule developed by Beijing Wehand-Bio Pharmaceutical. The drug is targeted toward the treatment of inflammatory and immunological diseases. It leverages the company's proprietary nanotechnology platform to improve the solubility and oral bioavailability of natural active ingredients, which often face delivery challenges due to poor aqueous solubility. WH003 is currently in the early stages of development within the sponsor's pipeline, categorized under their 'Other pipeline' assets for anti-inflammatory and immune-related indications.

Beyond the preview

Go deeper on WH003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WH003.

Explore the full profile